N-Acetyl Selank is the parent peptide Selank carrying a single acetyl cap on its N-terminus, and that one modification is the entire structural difference between the two molecules. Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at Russia's Institute of Molecular Genetics from the immune-signaling fragment tuftsin, and the acetylated analog shares that sequence while adding only the terminal cap. Neither form is an FDA-approved drug, published data on the acetylated variant are far thinner than for the parent, and any claim that one is more potent or longer-acting rests on inference rather than head-to-head measurement.
| Property | Selank | N-Acetyl Selank |
|---|---|---|
| Core sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Same heptapeptide sequence |
| N-terminus | Free alpha-amino group | Acetyl-capped amide |
| Evidence base | Russian anxiolytic/nootropic studies | Sparse; mostly inferred from Selank |
| Regulatory status | Not FDA-approved (clinical use in Russia) | Not FDA-approved; research chemical |
N-Acetyl Selank differs from Selank by a single N-terminal acetyl cap on the shared heptapeptide sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, and neither peptide is an FDA-approved drug.
Selank was engineered in Russia at the Institute of Molecular Genetics of the Russian Academy of Sciences, working with the V.V. Zakusov Institute of Pharmacology, to stabilize the activity of a natural immune-signaling fragment. Its parent is tuftsin, a four-residue peptide (Thr-Lys-Pro-Arg) released from the immunoglobulin heavy chain, which the bloodstream degrades very quickly on its own. The designers appended a Pro-Gly-Pro tripeptide to extend tuftsin's usable duration, yielding the heptapeptide that circulates outside Russia as a research compound rather than an approved medicine.
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) created at the Russian Academy of Sciences by extending the natural immunomodulatory fragment tuftsin with a stabilizing Pro-Gly-Pro tripeptide.
The N-terminus carries a free alpha-amino group that sits protonated and positively charged at physiological pH, which makes it both a target for enzymes and a contributor to the molecule's overall charge. N-terminal acetylation swaps one hydrogen on that group for an acetyl group (CH3CO), turning the basic amine into a neutral amide. It is one of the most common modifications in human proteins and is used routinely in synthetic peptide chemistry because it tends to improve metabolic stability without adding bulky or foreign chemical groups.
N-terminal acetylation converts the peptide's basic, positively charged amino terminus into a neutral amide, which raises lipophilicity and blocks the aminopeptidase recognition site without guaranteeing any change in biological potency.
The mechanistic case is straightforward: unmodified Selank still presents a free N-terminal threonine that aminopeptidases can trim, so capping that end should close off the remaining entry point and let the acetylated analog resist terminal degradation somewhat better. What the published record lacks is measurement. Rigorous pharmacokinetic studies comparing the half-life of N-Acetyl Selank against ordinary Selank under identical conditions are scarce to nonexistent, so the longer-duration claim rests on general acetylation chemistry rather than demonstrated data for this specific pair.
A stability advantage for N-Acetyl Selank is chemically plausible because the acetyl cap blocks the remaining aminopeptidase site, but no rigorous published pharmacokinetic study quantifies a half-life difference between the two forms.
Nearly all of the studied biology belongs to Selank, not to the acetylated variant. Russian preclinical and small clinical reports describe Selank mainly as an anxiolytic that reduces anxiety without the sedation or dependence tied to benzodiazepines, and secondarily as a mild nootropic in animal models and small human samples. The proposed mechanisms and the immunomodulatory activity inherited from tuftsin sit on a modest evidence base that large, independent, placebo-controlled trials have not confirmed.
The anxiolytic and nootropic effects on record belong to Selank itself, studied largely in small Russian trials, and the N-acetylated analog is assumed to share them without separate published validation.
Selank and its analog are delivered by intranasal solution or subcutaneous injection precisely because small peptides make poor oral drugs, since stomach acid, digestive proteases, and a charged hydrophilic structure drive oral bioavailability toward negligible. The relevant question is whether capping the N-terminus meaningfully improves uptake by the routes that are actually used. A directional argument exists, but the accessible literature holds no direct bioavailability comparison of the two forms by a defined route, so any specific absorption figure is an estimate rather than a demonstrated value.
Both peptides are dosed intranasally or subcutaneously because oral bioavailability is negligible, and no published study measures whether N-acetylation improves absorption of Selank by any defined route.
Neither Selank nor N-Acetyl Selank is approved by the U.S. Food and Drug Administration or the European Medicines Agency for diagnosing, treating, or preventing any condition. In the United States both are supplied as research chemicals labeled for laboratory use and marked not for human consumption, and marketing either with therapeutic claims for human use would run afoul of drug-marketing rules. The picture varies by country, since Selank has been used clinically within Russia under its own national approval framework, so calling it unapproved is accurate for the United States and much of the world but not universal.
Neither Selank nor N-Acetyl Selank is FDA- or EMA-approved and both are sold in the United States as research chemicals not for human consumption, though neither is a federally scheduled controlled substance and Selank is used clinically within Russia.
Direct, peer-reviewed research naming N-Acetyl Selank as the tested compound is sparse, and most descriptions of the analog borrow the record built for Selank, presenting effects, mechanisms, and dosing conventions established for the parent as though they transfer intact. That extrapolation is reasonable given how minor the structural change is, but it is an inference rather than a finding, and a great deal of the promotional material online blurs the line. No substantial body of published clinical trials has evaluated the acetylated form on its own.
No substantial body of peer-reviewed clinical trials has tested N-Acetyl Selank as the named compound, so its reported effects are borrowed by inference from Selank rather than independently demonstrated.
Short-term tolerability for Selank reads as generally favorable in the available literature, with mild adverse events and none of the sedation, dependence, or withdrawal tied to conventional anxiety drugs, but that picture sits on a thin evidence base and describes the parent peptide rather than the separately uncharacterized acetylated analog. The larger unknowns are long-term and population-level, since chronic exposure, vulnerable groups, rare adverse events, and drug interactions remain largely unmapped. A distinct hazard comes from sourcing, because research chemicals are made without the quality controls that govern approved medicines, so purity, identity, and dosing accuracy cannot be assumed.
The favorable short-term tolerability on record applies to Selank rather than the uncharacterized acetylated analog, and the absence of regulated manufacturing means purity, identity, dosing accuracy, and long-term safety cannot be assumed.
Educational use only. This article describes what the published scientific and clinical literature reports about N-Acetyl Selank and Selank. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
